$SPRB News

Last published 1d ago

1d agoSPRBGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SPRUCE BIOSCIENCES INCEarnings Call TranscriptsAll right, good morning, and thank you for joining Guggenheim's third Annual Healthcare Innovations Conference. I'm Debjit, and my privilege to welcome Javier Schwarzberg. Did I get that right? Perfectly pronounced. CEO
1d agoSPRBGuggenheim 3rd Annual Healthcare Innovation Conference - SPRUCE BIOSCIENCES INCEarnings Call TranscriptsAll right, good morning, and thank you for joining Guggenheim's third Annual Healthcare Innovations Conference. I'm Debjit, and my privilege to welcome Javier Schwarzberg. Did I get that right? Perfectly pronounced. CEO
2d agoSPRBSPRUCE BIOSCIENCES, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2d agoSPRBSpruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates. “We are executing with discipline as we ...
2d agoSPRBSpruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx BiosciencesBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has separated the company's CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, Inc. ("Adrenyx"), a newly formed wholl ...
2w agoSPRBSpruce Biosciences (SPRB) Fireside Chat - SPRUCE BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, everyone. I'm Albert Lowe, Senior Biotech Analyst. We've had a really great day of fireside chats, and I'm happy to close it out with Javier Schwartberg, the CEO of Spruce Biosciences. If anyone in the li
3w agoSPRBSpruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst ConferenceBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
1mo agoSPRBSpruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
2mo agoSPRBSpruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
2mo agoSPRBSpruce Biosciences Announces Launch of MPS3BStudy.comBusiness WireWebsite Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study TA-ERT EAP and TrAnsform
2mo agoSPRBSpruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026Business WireFDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer Spruce and FDA Aligned
3mo agoSPRBSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesBusiness WireBiologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected
3mo agoSPRBCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesBusiness WireInvestment Broadens Patient Access to Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B in the TA-ERT Expanded Access Program (EAP) TA-ERT EAP Expected to Initiate in the Fourth
3mo agoSPRBSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical DevelopmentBusiness WireDr. Cohen Pfeffer Brings More Than a Decade of Clinical Development Leadership, Including Deep Experience with Enzyme Replacement Therapies for Rare Pediatric Neurodegenerative DisordersSpruce Biosciences, Inc.
3mo agoSPRBSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical OfficerBusiness WireAccomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and
4mo agoSPRUCEBIO SPRBSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare SummitBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
4mo agoSPRBSpruce Biosciences Joins the Russell 3000® IndexBusiness WireInclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for
4mo agoSPRBSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical AffairsBusiness WireDr. Jurecka Brings Deep Enzyme Replacement Therapy and Rare Disease Experience to Lead Medical Affairs and Scientific Engagement Ahead of Potential U.S. FDA Approval of Tralesinidase Alfa Enzyme Replacement Therapy
4mo agoSPRBSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerBusiness WireAppointments Further Strengthen Spruce's Commercial and Financial Capabilities as the Company Approaches a Potential U.S. FDA Approval and Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for
5mo agoSPRBSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumBusiness WireData Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved Therapies Treatment With Weekly TA-ERT Demonstrated Rapid and Durable Normalization of
5mo agoSPRBJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - SPRUCE BIOSCIENCES INCEarnings Call TranscriptsGood morning, and welcome to the Jeffries Global Healthcare Conference in New York. My name is Nick Pecora with the Jefferies Investment Banking Team, and it is my great pleasure to introduce Javier Swardberg, CEO of Spr
5mo agoSPRBSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumBusiness WireNicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on
5mo agoSPRBSpruce Biosciences to Participate in Upcoming Conferences in JuneBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
6mo agoSPRBSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesBusiness WireLong-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened
6mo agoSPRBSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial OperationsBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
6mo agoSPRBSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireSpruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical
6mo agoSPRBSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireSpruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical
8mo agoSPRBSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesBusiness WireFollowing Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial
8mo agoSPRBSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerBusiness WireMr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage
8mo agoSPRBSpruce Biosciences to Present at Upcoming Investor Conferences in MarchBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
8mo agoSPRBSpruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Business WireBased on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the
8mo agoSPRBSpruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
9mo agoSPRBLong-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)Business WireTreatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical
9mo agoSPRBSpruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership TeamBusiness WireDaven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development Operations Spruce Biosciences, Inc.
9mo agoSPRBSpruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™Business WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced
9mo agoSPRBHarbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic CollaborationPR NewswireHarbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in...
10mo agoSPRBSpruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue CapitalBusiness WireInitial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB Spruce Biosciences, Inc.
11mo agoSPRBSpruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of DirectorsBusiness WireKeli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company
1y agoSPRBSpruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesBusiness WireGranted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for the
1y agoSPRBSpruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)Business WireBreakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE) U.S. FDA Confirmed that CSF HS-NRE is
1y agoSPRBSpruce Biosciences Resumes Trading on the Nasdaq Capital MarketBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it
1y agoSPRBSpruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesBusiness WireIntegrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) Biologics
1y agoSPRBSpruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)Business WireTA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in MPS IIIB U.S. FDA Confirmed that CSF HS-NRE is a Surrogate
1y agoSPRBSpruce Biosciences Announces Reverse Stock SplitBusiness WireSpruce's Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following Compliance with Minimum Bid Price for 20 Consecutive Trading
1y agoSPRBHMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive DisorderGlobeNewswireStudy Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif.,
1y agoSPRBSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Business WireBiologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences,
1y agoSPRBSpruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAHBusiness WireCAHmelia-204 Study of 200mg Once-Daily (QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction Dose-Ranging Data from CAHptain-205 Study of
2y agoSPRBSpruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness WireTopline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH
2y agoSPRBSpruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation ConferenceBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need,
2y agoSPRBSpruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need,